Skip to content
★ Sign in to follow
CC

Cardiogenesis Corp /CA Stock: price and insider trades · United States

No insider purchase over the last 90 days. The latest, by CRYOLIFE INC, was filed 19 May 2011.

Cardiogenesis Corp /CA: what insiders have been doing

Cardiogenesis Corp /CA is a listed company. Filings by its managers are published through SEC (Form 4). Nothing new has been filed by managers of Cardiogenesis Corp /CA in twelve months, the latest record being from 19 May 2011.

Over the whole record (from 2006), the tally stands at 13 purchases and 3 sales.

Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Insider Decl.
34
Thresholds
n/a
Buy Volume
€8M
13 ops. · all time
Sell Volume
€56,743
3 ops. · all time
Last declaration on 19 May 2011
Declarations34 total
  • ▲
    Related company / holdingExecutives
    11M USD0SEC
    23,401,043 shares@ US$0.457Common StockSEC:0000914062-11-000275:0
    Canonical exit: 15 Aug 2011 (T+90)
  • ●
    Executive VP, MarketingExecutives
    0SEC
    231,895 sharesCommon StockSEC:0001209191-11-028899:0
  • ●
    Executive ChairmanExecutives
    0SEC
    978,926 sharesCommon StockSEC:0001209191-11-028841:0
  • ●
    Senior VP, CFOExecutives
    0SEC
    66,038 sharesCommon StockSEC:0001209191-11-028874:0
  • ◆
    Executive ChairmanExecutives
    0SEC
    100,000 shares0Common StockSEC:0001209191-10-029000:0
  • ◆
    Executive VP, MarketingExecutives
    5,119 USD0SEC
    13,471 shares@ US$0.38Common StockSEC:0001209191-10-021214:0
  • ◆
    Senior VP, CFOExecutives
    4,137 USD0SEC
    10,886 shares@ US$0.38Common StockSEC:0001209191-10-021215:0
  • ◆
    Executive ChairmanExecutives
    24,000 USD0SEC
    120,000 shares@ US$0.20Common StockSEC:0001209191-09-043607:0
  • ◆
    Executive ChairmanExecutives
    1,407 USD0SEC
    7,403 shares@ US$0.19Common StockSEC:0001209191-09-042966:0
  • ◆
    Executive ChairmanExecutives
    200 USD0SEC
    1,050 shares@ US$0.19Common StockSEC:0001209191-09-042966:1
  • ◆
    Executive ChairmanExecutives
    7,333 USD0SEC
    34,920 shares@ US$0.21Common StockSEC:0001209191-09-041818:0
  • ◆
    Executive ChairmanExecutives
    190 USD0SEC
    1,000 shares@ US$0.19Common StockSEC:0001209191-09-041818:1
  • ◆
    Executive ChairmanExecutives
    4,420 USD0SEC
    22,100 shares@ US$0.20Common StockSEC:0001209191-09-041466:0
  • ◆
    Executive ChairmanExecutives
    1,580 USD0SEC
    7,900 shares@ US$0.20Common StockSEC:0001209191-09-041466:1
  • ◆
    Executive ChairmanExecutives
    965 USD0SEC
    5,080 shares@ US$0.19Common StockSEC:0001209191-09-041466:2
  • ◆
    Executive ChairmanExecutives
    57,000 USD0SEC
    300,000 shares@ US$0.19Common StockSEC:0001209191-09-034677:0
  • ◆
    PresidentExecutives
    0SEC
    95,193 shares0Common stockSEC:0001209191-09-019354:0
  • ◆
    Sr VP, CFOExecutives
    0SEC
    76,924 shares0Common StockSEC:0001209191-09-019353:0
  • ▲
    DirectorExecutives
    10,200 USD0SEC
    60,000 shares@ US$0.17Common StockSEC:0001209191-08-062004:0
    Canonical exit: 17 Feb 2009 (T+90)
  • ▲
    DirectorExecutives
    3,915 USD0SEC
    13,500 shares@ US$0.29Common StockSEC:0001209191-08-032427:0
    Canonical exit: 18 Aug 2008 (T+90)
  • ▲
    DirectorExecutives
    7,800 USD0SEC
    26,000 shares@ US$0.30Common StockSEC:0001209191-08-032427:1
    Canonical exit: 18 Aug 2008 (T+90)
  • ▲
    DirectorExecutives
    2,700 USD0SEC
    10,000 shares@ US$0.27Common StockSEC:0001209191-08-032427:2
    Canonical exit: 18 Aug 2008 (T+90)
  • ▲
    DirectorExecutives
    9,000 USD0SEC
    30,000 shares@ US$0.30Common StockSEC:0001209191-08-032427:3
    Canonical exit: 19 Aug 2008 (T+90)
  • ▲
    DirectorExecutives
    4,095 USD0SEC
    20,473 shares@ US$0.20Common StockSEC:0001209191-07-049462:0
    Canonical exit: 15 Nov 2007 (T+90)
  • ▼
    DirectorExecutives
    22,000 USD0SEC
    100,000 shares@ US$0.22Common StockSEC:0001209191-07-048899:0

25 of 34 declarations

About Cardiogenesis Corp /CA

CARDIOGENESIS CORP is a company listed on the XNAS market, focused on developing medical technologies for the treatment of heart diseases.